United Therapeutics

Why Shares of MannKind Were Up Wednesday
Why Shares of MannKind Were Up Wednesday
Motley Fool
MannKind
earnings
United Therapeutics
Flag link:
Biopharmas left Black and Latinx patients behind in oncology clinical trials, nonprofit says
Biopharmas left Black and Latinx patients behind in oncology clinical trials, nonprofit says
Fierce Biotech
clinical trials
clinical trial diversity
oncology
Sanofi
United Therapeutics
Bristol Myers Squibb
Flag link:
Gossamer could put pressure on Merck
Gossamer could put pressure on Merck
EP Vantage
Merck
Gossamer Bio
PAH
sotatercept
United Therapeutics
ralinepag
Flag link:
United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease
United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease
Yahoo/Benzinga
United Therapeutics
Tyvaso
COPD
clinical trials
Flag link:
Long after first nod for inhaled Tyvaso, United Therapeutics scraps PhIII in PH with COPD
Long after first nod for inhaled Tyvaso, United Therapeutics scraps PhIII in PH with COPD
Endpoints
Tyvaso
United Therapeutics
PAH
clinical trials
Flag link:
United Therapeutics Provides an Update on Its Organ Printing Programs
United Therapeutics Provides an Update on Its Organ Printing Programs
BioSpace
United Therapeutics
organ printing
Medtech
3D Systems
lung scaffolds
Flag link:
Another day, another xenotransplant, as United Therapeutics looks to beat competitors to sci-fi-esque breakthrough
Another day, another xenotransplant, as United Therapeutics looks to beat competitors to sci-fi-esque breakthrough
Endpoints
United Therapeutics
xenotransplants
Revivicor
Medtech
Flag link:
Judge rules HHS' letter enforcing 340B discounts was 'arbitrary'
Judge rules HHS' letter enforcing 340B discounts was 'arbitrary'
Beckers Hospital Review
HHS
drug pricing
340B
AstraZeneca
Eli Lilly
Novo Nordisk
Sanofi
United Therapeutics
Flag link:
FDA declines to approve United-MannKind's lung disease therapy
FDA declines to approve United-MannKind's lung disease therapy
Yahoo/Reuters
MannKind
United Therapeutics
Tyvaso
FDA
PAH
Flag link:
HHS lines up Novartis, Lilly, AstraZeneca and 3 other drugmakers for fines due to drug discount violations
HHS lines up Novartis, Lilly, AstraZeneca and 3 other drugmakers for fines due to drug discount violations
Endpoints
HHS
340B
discounts
Novartis
Eli Lilly
AstraZeneca
Novo Nordisk
Sanofi
United Therapeutics
Flag link:
MannKind and United Snag Priority Review for Pulmonary Hypertension Drug
MannKind and United Snag Priority Review for Pulmonary Hypertension Drug
BioSpace
MannKind
United Therapeutics
PAH
PH-ILD
FDA
priority review
Tyvaso
Flag link:
United Therapeutics: FDA Approves Tyvaso For PH-ILD
United Therapeutics: FDA Approves Tyvaso For PH-ILD
NASDAQ
United Therapeutics
FDA
Tyvaso
PH-ILD
pulmonary hypertension
Flag link:
United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback
United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback
Endpoints
United Therapeutics
Trevyent
PAH
SteadyMed
Flag link:
Corporate and regulatory developments over the holidays
Corporate and regulatory developments over the holidays
EP Vantage
AstraZeneca
Bristol-Myers Squibb
Celltrion
Cullinan Oncology
JNJ
Myovant Sciences
Osmotica Pharmaceuticals
Pfizer
Y-mAbs Therapeutics
United Therapeutics
Zai Lab
Flag link:
With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso
With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso
Endpoints
United Therapeutics
Tyvaso
priority review voucher
PAH
Flag link:
United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial
United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial
Xconomy
United Therapeutics
clinical trials
Unituxin
small cell lung cancer
Flag link:
Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin
Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin
Fierce Pharma
Novartis
Sandoz
United Therapeutics
Remodulin
Flag link:
Acceleron’s post-Reblozyl plan comes together
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Acceleron
sotatercept
PAH
JNJ
Bellerophon Therapeutics
United Therapeutics
Vivus
Arena
Novartis
Flag link:
Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst
Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst
EP Vantage
United Therapeutics
Unituxin
SCLC
Biogen
MAb BIIB092
Flag link:
United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug
United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug
BioSpace
United Therapeutics
PAH
Remodulin
generics
Sandoz
Flag link:

Pages